Scientists Propose Artificial Intelligence and Multi-Omics Framework for Perinatal Psychiatric Dosing

Peripartum mental health disorders constitute an enormous population health burden, affecting an estimated 10% of pregnant women globally and 13% of women in the postpartum period, yet timely diagnosis and therapy remain hindered by subjective screening tools and clinical judgment that lack objective specificity. A comprehensive scientific review published in AAPS Open by Mohamed A. Ismail outlines an integrative framework for precision perinatal psychiatry designed to overcome high rates of treatment failure and adverse drug reactions. The proposed clinical roadmap combines pharmacogenomics, dynamic multi-omics profiling, therapeutic drug monitoring, and artificial intelligence-informed physiologically based pharmacokinetic modeling. Rather than relying on static genetic snapshots or trial-and-error prescribing that fails to benefit many women, this system-level paradigm seeks to dynamically anticipate and manage the volatile biological and pharmacological oscillations characteristic of gestation and lactation, establishing an objective foundation for individualized, effective, and safe psychiatric interventions across the mother-infant dyad.

Pregnancy initiates profound and rapid physiological transformations that fundamentally alter maternal drug disposition across absorption, distribution, metabolism, and excretion. Elevated progesterone concentrations exert a direct relaxing effect on smooth muscle tissue, resulting in delayed gastric emptying and diminished intestinal bowel motility, which systematically slows and modifies the rate of drug absorption into maternal circulation. Concurrently, marked maternal physiological hypervolemia expands circulating plasma volume by up to fifty percent, drastically widening the volume of distribution for lipophilic psychotropic compounds while circulating plasma albumin concentrations drop, substantially diminishing available plasma protein binding capacity. Meanwhile, substantial increases in maternal cardiac output and circulating blood volume elevate renal blood flow and glomerular filtration rates, driving accelerated renal excretion of polar psychiatric medications such as lithium. Because this enhanced renal drug clearance reverses rapidly and dramatically following delivery, patients face an immediate postpartum risk of maternal drug toxicity unless dosage levels are quickly reduced.

Hepatic drug clearance during pregnancy is governed by an intricate pattern of hormonal dual regulation driven by surging circulating sex steroid concentrations that concurrently induce and inhibit specific metabolic pathways. Elevated gestational steroids induce phase 1 and phase 2 hepatic enzymes, notably cytochrome P450 3A4 and uridine 5′-diphospho-glucuronosyltransferases, accelerating the systemic elimination of critical therapeutic medications. For example, circulating plasma levels of the mood stabilizer lamotrigine can plummet by approximately fifty percent during gestation, frequently requiring progressive dose escalations of up to three times baseline in early and mid-pregnancy and up to five times baseline in late pregnancy to maintain clinical efficacy. In contrast, circulating gestational hormones concurrently inhibit other vital phase 1 enzymes, including cytochrome P450 1A2 and cytochrome P450 2C19. Cytochrome P450 1A2 metabolic activity may decline by up to sixty-five percent by the third trimester compared to non-pregnant baselines, demonstrating that standard, static metabolic assumptions fail during gestation.

These transient, hormone-driven metabolic alterations frequently decouple a patient’s functional metabolic performance from their baseline inherited genotype, creating clinically hazardous discordances between predicted and observed psychotropic drug disposition. In individuals classified genetically as normal metabolizers or ultrarapid metabolizers, accelerated physiological clearance can swiftly render psychotropic drug concentrations subtherapeutic, precipitating treatment failure and the relapse of depressive symptoms. Conversely, being a genetically identified cytochrome P450 2D6 poor metabolizer is associated with a fourfold increased risk of discontinuing antidepressant therapy during pregnancy. Furthermore, pregnant women possessing an extensive metabolizer genotype for cytochrome P450 2C19 who typically eliminate citalopram rapidly can experience marked third-trimester hormonal inhibition that temporarily shifts functional metabolic status to intermediate or poor metabolizer phenotypes, triggering unanticipated drug accumulation and toxicity. Similar enzyme shifts occur with cytochrome P450 2D6, which is induced during pregnancy to shift genetic normal metabolizers into functional ultrarapid metabolizers, compounding polypharmacy risks.

To navigate these volatile physiological shifts, the review emphasizes pairing baseline pharmacogenomics with systematic therapeutic drug monitoring to measure real-time circulating drug concentrations during gestation and the immediate postpartum period. While pharmacogenomics establishes the static baseline potential for drug metabolism, therapeutic drug monitoring provides a dynamic empirical tool to quantify actual plasma concentrations, guiding intervention-dependent dose adjustments that transcend standard drug labeling recommendations for narrow therapeutic index medications like lithium and volatilely cleared agents like lamotrigine. Beyond metabolic clearance, the framework incorporates pharmacodynamic genes and barrier transport proteins. Polymorphisms in the serotonin transporter gene SLC6A4 and the serotonin-2A receptor gene HTR2A independently govern treatment response, remission rates, and adverse effects, with specific SLC6A4 variants linked directly to postpartum depression. Concurrently, polymorphisms in the ABCB1 gene encoding the placental P-glycoprotein efflux pump modulate fetal drug exposure and potential congenital risks, while cytochrome P450 2D6 ultrarapid metabolism of codeine to morphine poses life-threatening neonatal respiratory depression risks via breast milk.

Traditional pharmacogenomic paradigms relying on candidate gene associations, single nucleotide polymorphisms, and copy number variations fail to capture the complex, polygenic, and environmentally mediated nature of perinatal psychiatric disorders. To overcome the static limitations of single-gene testing, the proposed roadmap advances a multi-omics pyramid that systematically layers genomics, transcriptomics, proteomics, and metabolomics into an integrated systems-biology model. By tracking longitudinal molecular alterations, this multi-tiered architecture captures dynamic cellular functional states rather than static inherited genetic risk alone, reflecting real-time immune, metabolic, and endocrine shifts across the mother-infant dyad. High-dimensional multi-omics datasets can therefore uncover latent disease signatures, identify hub regulatory biomarkers, and characterize the biological crosstalk between maternal, placental, and fetal compartments, generating the actionable biological depth necessary to proactively safeguard maternal psychological stability while simultaneously protecting developing fetal systems from unexpected pharmacological toxicity and adverse drug reactions.

Interpreting high-dimensional, heterogeneous pharmaco-multiomics datasets requires advanced computational machinery because conventional frequentist statistics and univariate candidate gene models struggle with the curse of dimensionality and longitudinal data sparsity in clinical perinatal cohorts. Machine learning architectures, particularly deep learning models, provide the analytical tools necessary to harmoniously synthesize disparate data streams ranging from discrete genomic sequences to continuous metabolomic profiles, clinical texts, and imaging records. Graph neural networks represent a critical methodological breakthrough, modeling the biologically interacting mother-placenta-fetus triad as a dynamic biological graph where molecular entities operate as nodes and biochemical pathways serve as connecting edges. By simulating how pharmacological perturbations introduced into maternal subgraphs propagate across placental interfaces to fetal subgraphs, graph neural networks directly address fetal safety prediction. Simultaneously, variational autoencoders and deep generative methods construct compressed latent representations to perform data imputation, harmonize cohorts, and correct batch effects across gestational timepoints.

To ensure that complex computational models achieve clinical utility, the review underscores the vital role of explainable artificial intelligence architectures, particularly cross-modal attention mechanisms. Unlike late-fusion strategies that merely combine pre-processed outputs from isolated submodels, cross-modal attention implemented via transformer multi-head self-attention networks enables a unified deep neural network to dynamically weigh and align features across disparate raw biological streams in real time. This architectural capability captures context-dependent, non-linear interactions connecting genomic variants, circulating protein concentrations, and gestational hormonal fluctuations. Recent integrative investigations combining transformer attention mechanisms with graph convolutional networks have demonstrated superior performance in capturing higher-order cross-omic interactions across genomics, transcriptomics, and metabolomics. Similarly, perinatal machine learning studies applying multi-modal attention networks to maternal blood transcriptomics have successfully highlighted dysregulated neuroplasticity and glucocorticoid signaling genes as salient predictive features for subsequent depression, generating testable biological hypotheses while building clinician trust.

The operational culmination of this framework is a translational two-stage precision dosing pipeline that integrates classification-based machine learning with mechanistic physiologically based pharmacokinetic modeling. In the first phase of this pipeline, supervised classification algorithms, including random forest models and artificial neural networks, are trained on genomic drug-metabolizing enzyme variants to determine each patient’s stable metabolic phenotype with high confidence. In the second phase, this predicted phenotype is deployed as an immovable genetic anchor within a mechanistic pharmacokinetic simulation platform, onto which time-varying gestational physiological parameters are continuously overlaid. These dynamic parameters incorporate maternal blood volume expansion, shifting plasma protein binding, altered organ blood flow, and fluctuating hepatic enzyme inductions. This hybrid computational workflow translates complex genomic profiles and transient physiological fluctuations into quantitative, individualized dosage adjustments across each trimester of pregnancy and into the postpartum period, converting abstract biological markers into actionable clinical prescribing decisions.

Despite the conceptual maturity of this precision roadmap, the review identifies formidable translational, methodological, and ethical hurdles that must be resolved prior to routine clinical implementation in obstetric and psychiatric care. Most existing predictive models remain exploratory proofs of concept applied to small, homogeneous retrospective cohorts that lack the granular longitudinal data required for robust validation in dynamic perinatal settings. Addressing these limitations demands establishing large, multicenter prospective cohorts that capture comprehensive multi-omics, clinical, and social determinants data, while developing transparent explainable artificial intelligence algorithms to overcome black-box opacity. Furthermore, prominent ethical, legal, and social implications surrounding maternal data privacy, informed consent, algorithmic bias, and equitable access must be proactively addressed. Finally, bridging the research-to-clinic divide necessitates structured clinician education programs and the integration of explainable decision-support tools into electronic health records, ensuring that future precision perinatal psychiatry can reliably safeguard maternal-infant health.

Subject of Research: Precision perinatal psychiatry using multi-omics and artificial intelligence

Article Title: A roadmap to tomorrow's clinic: integrating pharmaco-multiomics and AI for precision perinatal psychiatry

Article References: Ismail, M. A. (2026). A roadmap to tomorrow's clinic: integrating pharmaco-multiomics and AI for precision perinatal psychiatry. AAPS Open, 12(1), Article 25. https://doi.org/10.1186/s41120-026-00165-3

Image Credits: AI Generated

DOI: 10.1186/s41120-026-00165-3

Keywords: peripartum mental health disorders, precision perinatal psychiatry, pharmacogenomics, therapeutic drug monitoring, physiologically based pharmacokinetic modeling, multi-omics integration, graph neural networks, variational autoencoders, cross-modal attention, gestational pharmacokinetics, cytochrome P450 enzymes, lamotrigine clearance, lithium renal excretion, placental ABCB1 transport, explainable artificial intelligence, postpartum depression biomarkers, adverse drug reaction prediction